This paper is in the following e-collection/theme issue:

Clinical Information and Decision Making (1929) Decision Support for Health Professionals (1550) Clinical Informatics (1328)

Published on in Vol 24, No 6 (2022): June

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/33446, first published .
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis

Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis

Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis

Authors of this article:

Rawa Kamaran Ismail1 Author Orcid Image ;   Jesper van Breeschoten2 Author Orcid Image ;   Silvia van der Flier3 Author Orcid Image ;   Caspar van Loosen4 Author Orcid Image ;   Anna Maria Gerdina Pasmooij5 Author Orcid Image ;   Maaike van Dartel5 Author Orcid Image ;   Alfons van den Eertwegh6 Author Orcid Image ;   Anthonius de Boer1 Author Orcid Image ;   Michel Wouters7 Author Orcid Image ;   Doranne Hilarius8 Author Orcid Image
Article Authors Cited by (2) Tweetations (5) Metrics

Journals

  1. Grit G, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, JM Smit H, Brocken P, FH Eijsink J, Dronkers E, Gal P, Jaarsma E, JHM van Drie-Pierik R, MP Eldering-Heldens A, Machteld Wymenga A, GM Mol P, Zwaveling J, Hilarius D. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective. Lung Cancer 2024;196:107950 View
  2. Peters B, van Geffen E, Hilarius D, Böhringer S, Zwaveling J, Dronkers E, van der Leest C, Smit H. The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell Lung cancer. Lung Cancer 2025;206:108642 View